Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 4/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.31 |
| ▸ | FLT1 | P17948 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22122943 | 1.00 | PTK6 (0.40) | PTK6IRAK4ALDH1A1SMN1; SMN2GSK3B | |
| SCHEMBL30171800 | 0.96 | PTK6 (0.39) | PTK6ALDH1A1SMN1; SMN2TTKMAPKAPK5 | |
| SCHEMBL22123298 | 0.96 | PTK6 (0.39) | PTK6ALDH1A1SMN1; SMN2TTKMAPKAPK5 | |
| SCHEMBL22122963 | 0.95 | PTK6 (0.40) | PTK6IRAK4ALDH1A1SMN1; SMN2GSK3B | |
| SCHEMBL30171866 | 0.95 | PTK6 (0.40) | PTK6IRAK4ALDH1A1SMN1; SMN2GSK3B | |
| SCHEMBL22122868 | 0.95 | PTK6 (0.40) | PTK6IRAK4ALDH1A1SMN1; SMN2GSK3B | |
| SCHEMBL30172001 | 0.95 | PTK6 (0.40) | PTK6IRAK4ALDH1A1SMN1; SMN2GSK3B | |
| SCHEMBL24112493 | 0.89 | PTK6 (0.41) | PTK6IRAK4TTKMAPKAPK5 | |
| SCHEMBL22122941 | 0.89 | PTK6 (0.41) | PTK6SMN1; SMN2CDK2TTKMAPKAPK5 | |
| SCHEMBL30171741 | 0.89 | PTK6 (0.41) | PTK6SMN1; SMN2CDK2TTKMAPKAPK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898630-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2023-05-10 | — | — | EP | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885IRAK4 55/4885ALDH1A1 539/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2201/4885IRAK4 55/4885ALDH1A1 539/4885 |
| US-20230017532-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | PTK6 2141/4885IRAK4 35/4885ALDH1A1 540/4885 |
| US-20230013602-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | IL4, RPS4Y1, RPS4X | PTK6 1818/4885IRAK4 18/4885ALDH1A1 1264/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK6 2211/4885IRAK4 30/4885ALDH1A1 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.